Immix Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a novel class of tissue-specific therapeutics in oncology and inflammation to treat inflammatory bowel disease, including ulcerative colitis and crohn's diseases. Immix Biopharma serves customers in the United States.